Clinical trials: Hypersensitivity
Hearing Impairment
Evaluation of Carina Microphone Sensitivity and Maximum Stable Gain in Adult Recipients
This investigation is a single-centre, prospective, single-arm, post-market, non-interventional, pilot clinical investigation designed to characterize microphone sensitivity and maximum stable gain of the Cochlear Carina System.
- Trial name
- CAMSEN (NCT04271761)
- Testing
- Non-interventional, post-market, pilot study of Carina Cochlear System
- Where
- Portugal
- Volunteers
- 14 people
- Sponsor
- Cochlear
Seasonal Allergic Rhinitis
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life
- Trial name
- NCT00621959
- Testing
- levocetirizine dihydrochloride
- Where
- 26 sites in United States
- Volunteers
- 596 people
- Sponsor
- UCB Pharma
Advanced Stage Non-small Cell Lung Cancer
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.
- Trial name
- NCT02350764
- Testing
- nivolumab, pilimumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Asthma
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in…
- Trial name
- ARIA (NCT02821416)
- Testing
- Benralizumab
- Where
- 6 sites in Canada
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Perennial Allergic Rhinitis
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (subjects 12 years of age and older)
- Trial name
- GSP 301-303 (NCT02709538)
- Testing
- GSP 301 NS
- Where
- 34 sites in United States
- Volunteers
- 601 people
- Sponsor
- Glenmark Specialty S.A.
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Trial name
- NCT05984784
- Testing
- IMG-007
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Inmagene LLC
Dentin Sensitivity
Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
This single centre, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a…
- Trial name
- NCT02731833
- Testing
- stannous fluoride, sodium monofluorophosphate
- Where
- Canada
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal…
- Trial name
- NCT02037347
- Testing
- Palifermin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brett King
Asthma
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment…
- Trial name
- NCT01867125
- Testing
- Lebrikizumab
- Where
- 181 sites in United States, Argentina and 24 more
- Volunteers
- 1,081 people
- Sponsor
- Hoffmann-La Roche
Cough
GSK2339345 Hypertussive Challenge Study
This study is designed to evaluate the effect of GSK2339345 relative to placebo on the number of coughs in patients with Chronic Idiopathic Cough (CIC) administered by an Aqueous Droplet Inhaler (ADI).
- Trial name
- NCT01899768
- Testing
- GSK2339345
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03985943
- Testing
- Nemolizumab
- Where
- 174 sites in United States, Australia and 12 more
- Volunteers
- 941 people
- Sponsor
- Galderma R&D
Asthma
CARE FOR ALL：an Evaluation of an Asthma QIP
This is an evaluation on an asthma Quality Improvement Program (QIP, including GINA guideline education/training and implementation) to understand the change of physician behaviours, which leads to the change of patient outcomes.
- Trial name
- CARE FOR ALL (NCT05440097)
- Testing
- QIP intervention
- Where
- 32 sites in China
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Asthma
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic…
- Trial name
- NCT00452348
- Testing
- Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
- Where
- 81 sites in United States, Argentina and 3 more
- Volunteers
- 628 people
- Sponsor
- GlaxoSmithKline
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in Chinese participants with mHSPC.
- Trial name
- NCT04934722
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 24 sites in China
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcoidosis
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
Sarcoidosis is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking lungs, heart, nerves, or other organs or systems within the body.
- Trial name
- NCT00282438
- Testing
- Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Asthma
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent…
- Trial name
- NCT01147848
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder
- Where
- 63 sites in United States, Argentina and 4 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma
This study is a multi-centre, randomised, double-blind, placebo-controlled (with rescue medication), two period crossover study in subjects with persistent uncontrolled asthma, currently not treated with an inhaled corticosteroid…
- Trial name
- NCT02567708
- Testing
- GSK2269557 DPI
- Where
- 12 sites in Germany
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
To investigate the effects of CAT-354 on airway hyper-responsiveness (AHR) in uncontrolled asthma.
- Trial name
- NCT00640016
- Testing
- CAT-354 1 mg/kg, CAT-354 5 mg/kg, CAT-354 10 mg/kg
- Where
- 41 sites in Australia, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.